Shamburg News · 8-K filed Nov 16, 2026, 4:45 PM EST

Traws Pharma Reports Q3 2026 Net Loss of $3.5 Million; Ratutrelvir Phase 2a Final Results

TRAW · Traws Pharma, Inc.

  • Earnings
  • Reg FD disclosure
  • Financing
  • Materiality: high

On November 16, 2026, Traws Pharma furnished a press release reporting a third-quarter 2026 net loss of $3.5 million, or $0.18 per share basic and diluted, compared with $4.0 million, or $0.34 per share, a year earlier. The company reported no revenue for the quarter and cash and cash equivalents of $2.3 million as of September 30, 2026. The release also described final Phase 2a results for ratutrelvir and a planned Q4 2026 toxicology resubmission for tivoxavir marboxil, and disclosed a $50 million common stock purchase agreement with Roth Principal Investments dated October 23, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001104659-26-128450.

Written from the filing by Shamburg Markets. Figures are as reported by the company.